Tryptamine Therapeutics, a clinical-stage pharmaceutical company, has secured AUD 6.5 million (USD 4.3 million) via its initial public offering.
Formed earlier this month through a merger between Tryp Therapeutics and Exopharm, Tryptamine Therapeutics is listed on the Australian Securities Exchange under the ticker symbol "TYP."
The new funds will be used toward advancing its pipeline of psilocin-based therapies into clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.